<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pharmadog.xyz/news/225063</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T20:32:45.000Z</news:publication_date>
      <news:title>Trump orders MMR vaccine to be administered as three separate shots, citing autism concerns</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224723</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T19:29:51.000Z</news:publication_date>
      <news:title>Trump administration issues executive order questioning childhood vaccine schedule</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224679</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T19:05:00.000Z</news:publication_date>
      <news:title>FDA rejects ITM&apos;s radiopharma drug for neuroendocrine tumors over manufacturing issues</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224454</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T18:20:19.000Z</news:publication_date>
      <news:title>Bristol Myers Squibb announces $2.3 billion manufacturing campus in Houston</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224295</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T17:43:22.000Z</news:publication_date>
      <news:title>Federal judge suspends Pentagon&apos;s designation of WuXi AppTec as a Chinese military-linked firm</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224339</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T17:36:47.000Z</news:publication_date>
      <news:title>BMS commits $2.3 billion to build modular manufacturing campus in Houston, creating 2,500 jobs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224178</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T17:08:01.000Z</news:publication_date>
      <news:title>Scholar Rock removes Indiana manufacturing site from SMA drug application after FDA cites deficiencies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224026</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T16:22:59.000Z</news:publication_date>
      <news:title>Sionna’s cystic fibrosis candidate misses primary endpoint in Phase 2 trial, shares plunge</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223803</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:39:45.000Z</news:publication_date>
      <news:title>Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to Vertex</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223907</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:36:00.000Z</news:publication_date>
      <news:title>Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billion</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223686</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:33:49.000Z</news:publication_date>
      <news:title>AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223687</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:33:02.000Z</news:publication_date>
      <news:title>RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 success</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223631</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:11:07.000Z</news:publication_date>
      <news:title>FDA rejects ITM-11 radiopharmaceutical over manufacturing flaws, halting rival to Novartis therapy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223632</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T15:00:00.000Z</news:publication_date>
      <news:title>FDA to require companies to notify agency of new food additives, creating public database</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223633</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:52:16.000Z</news:publication_date>
      <news:title>Calls to Ban Prior Authorizations Amid Hospital Job Cuts Highlight Health‑Care Policy Debate</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223611</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:50:01.000Z</news:publication_date>
      <news:title>Sionna’s Phase 2a CF trial fails, shares plunge as Vertex’s Trikafta remains standard of care</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/134233</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:49:00.000Z</news:publication_date>
      <news:title>CLINUVEL to cut up to 20% of staff and move headquarters to New York</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223634</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:48:07.000Z</news:publication_date>
      <news:title>FDA advisory panel set to review Grail’s multi-cancer Galleri screening test</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223613</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:42:33.000Z</news:publication_date>
      <news:title>Jazz Pharma to acquire Actio Biosciences for up to $1.3 billion, adding experimental KCNT1 epilepsy drug</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223474</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:37:15.000Z</news:publication_date>
      <news:title>Psychedelic firms Definium and Compass poised for key data releases</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223475</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:36:19.000Z</news:publication_date>
      <news:title>AstraZeneca and CSPC launch joint venture to build biologics plant in Shijiazhuang</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223543</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:30:00.000Z</news:publication_date>
      <news:title>Aspo Oyj announces upcoming leadership changes scheduled for August 10, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223542</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:30:00.000Z</news:publication_date>
      <news:title>Aspo Plc reports managers&apos; transactions on August 10, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224028</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T14:25:05.000Z</news:publication_date>
      <news:title>Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol gene</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223291</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T13:45:18.000Z</news:publication_date>
      <news:title>Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million upfront, targeting ultra-rare epilepsy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223355</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T13:24:23.000Z</news:publication_date>
      <news:title>Sanofi faces shortage of two Pompe disease drugs after FDA flags manufacturing issues</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223079</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T12:57:39.000Z</news:publication_date>
      <news:title>Tenax Therapeutics&apos; heart failure drug TNX-103 misses primary endpoint in Phase 3, shares plunge 85%</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222931</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T12:03:17.000Z</news:publication_date>
      <news:title>Sionna&apos;s CF add-on pill fails to improve outcomes in Phase 2 trial with Trikafta</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/123082</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:53:00.000Z</news:publication_date>
      <news:title>Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222803</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:38:20.000Z</news:publication_date>
      <news:title>Tenax Therapeutics’ heart-failure drug misses primary goal in Phase 3 trial, shares tumble</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222759</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:31:25.000Z</news:publication_date>
      <news:title>Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 success</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222804</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:31:00.000Z</news:publication_date>
      <news:title>Silence Therapeutics’ divesiran shows 88% response in Phase 2 polycythemia vera trial, challenging Takeda’s upcoming drug</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222784</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:20:01.000Z</news:publication_date>
      <news:title>BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme asset</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223661</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:09:00.000Z</news:publication_date>
      <news:title>FDA issues complete response letter rejecting ITM’s neuroendocrine tumor drug over manufacturing concerns</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222651</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T11:00:22.000Z</news:publication_date>
      <news:title>BioNTech veteran secures $25M seed round for virtual cancer surveillance startup</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222547</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T10:42:13.000Z</news:publication_date>
      <news:title>Denali Therapeutics&apos; Avlayah generates $3.6M in Q1, beating forecasts</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223425</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T10:09:00.000Z</news:publication_date>
      <news:title>Scholar Rock removes Novo Nordisk&apos;s Catalent plant from FDA filing for SMA drug apitegromab</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223662</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T10:00:00.000Z</news:publication_date>
      <news:title>MoonLake reports all endpoints met in phase 3 trial of sonelokimab for psoriatic arthritis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223562</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T09:48:00.000Z</news:publication_date>
      <news:title>Jazz Pharma to acquire Actio Biosciences for $820M, adding KCNT1+ epilepsy drug to its pipeline</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223426</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T09:39:00.000Z</news:publication_date>
      <news:title>Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222203</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T09:00:00.000Z</news:publication_date>
      <news:title>Early regulatory operations planning key to submission-ready dossiers</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222184</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:30:00.000Z</news:publication_date>
      <news:title>Global Ebola preparedness fixated on one strain, leaving gaps for other species</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222185</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:30:00.000Z</news:publication_date>
      <news:title>Safety concerns emerge as radiopharmaceuticals advance in cancer trials</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223360</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:30:00.000Z</news:publication_date>
      <news:title>Global Ebola preparedness fixated on one strain, leaving other species vulnerable</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222183</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:30:00.000Z</news:publication_date>
      <news:title>China clamps down on investigator-initiated clinical trials, tightening oversight</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222186</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:30:00.000Z</news:publication_date>
      <news:title>States urged to use low-cost, scalable outreach for Medicaid enrollees facing 2027 eligibility changes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223030</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:25:00.000Z</news:publication_date>
      <news:title>AbCellera&apos;s Phase 2 hot flash trial beats aggressive upside target, challenging Astellas and Bayer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223266</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:18:00.000Z</news:publication_date>
      <news:title>FDA approves Labcorp&apos;s BRAF melanoma companion diagnostic</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223031</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T08:14:00.000Z</news:publication_date>
      <news:title>FDA issues early alert after BD needle set defects linked to four deaths</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222843</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T07:15:00.000Z</news:publication_date>
      <news:title>Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/221739</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T07:12:00.000Z</news:publication_date>
      <news:title>AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purification</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222330</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T05:06:00.000Z</news:publication_date>
      <news:title>Arpeggio Biosciences shuts down after Nrf2 drug program encounters off-target toxicity</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222734</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:36:00.000Z</news:publication_date>
      <news:title>Silence Therapeutics’ Phase 2 Trial Shows Strong Efficacy of divesiran in Polycythemia Vera</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/222114</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:29:00.000Z</news:publication_date>
      <news:title>aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimod</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/221039</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:04:00.000Z</news:publication_date>
      <news:title>Biogen’s ALS drug shows symptom improvement in some patients three years after approval</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/221040</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:03:00.000Z</news:publication_date>
      <news:title>BMS&apos;s Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunity</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/221041</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:02:00.000Z</news:publication_date>
      <news:title>Eli Lilly&apos;s $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depression</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/224379</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T04:00:00.000Z</news:publication_date>
      <news:title>Abiomed and Oscor advise correction of Impella catheter introducers due to leakage risk</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/226616</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T00:00:00.000Z</news:publication_date>
      <news:title>BMS to build $2.3 B Houston plant as MHRA clears Lilly&apos;s weight-loss drug; IMDRF issues PCCP guidance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/226614</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T00:00:00.000Z</news:publication_date>
      <news:title>FDA issues warning letters to Indian OTC drugmaker over falsified logbooks and cites GMP lapses at two other firms</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/226615</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T00:00:00.000Z</news:publication_date>
      <news:title>India tightens penalties for submitting false regulatory documents</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/226613</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-10T00:00:00.000Z</news:publication_date>
      <news:title>IMDRF details key principles for regulators to adopt PCCPs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/220191</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-09T23:16:45.000Z</news:publication_date>
      <news:title>Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warning</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://pharmadog.xyz/news/223032</loc>
    <news:news>
      <news:publication>
        <news:name>pharmadog</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-09T22:33:00.000Z</news:publication_date>
      <news:title>Novo Nordisk and Amazon sign AI drug discovery pact, launch London innovation hub</news:title>
    </news:news>
  </url>
</urlset>
